ClinicalTrials.gg
CompletedNCT02718716Updated Jan 29, 2024Results posted

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

A Phase 2 interventional study of UCB7665 in Thrombocytopenia, sponsored by UCB Biopharma SRL. Completed at 29 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-29.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Thrombocytopenia with a site in Poland — 3 open to participants now, 4 under way, 3 of them phase 3. Thrombocytopenia · Poland.

Enrollment
16th of 21
66 · median 150
Started
2016
the only one that year
Phase 2
7 of 21
1 open now
Registered
14th of 21
by date

Among the 21 studies in Thrombocytopenia with a site in Poland, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 2, and was the 14th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

3 of the 21 studies in Thrombocytopenia with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Thrombocytopenia with a site in Poland, or all of them as a file.
02

Study summary

The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.

03

Conditions studied

  • Thrombocytopenia

Browse trials for

Keywords

  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a diagnosis of primary immune thrombocytopenia (ITP) for a minimum of 3 months prior to Screening Visit
  • Subject has a count \<30x10\^9/L at Screening and \<35x10\^9/L at Baseline (Visit 2)
  • Subject has a current or history of a peripheral blood smear consistent with ITP
  • Subject has responded to previous ITP therapy (according to the judgment of the investigator)

Exclusion criteria

Exclusion Criteria:

  • Subject has an immunoglobulin G (IgG) level \<=6g/L at Screening Visit
  • Subject has a (PTT) >=1.5x (ULN) or International Normalized Ratio (INR) >=1.5 at Screening Visit
  • Subject has renal and/or liver impairment defined as:

    • Serum creatinine level of >=1.4 mg/dL for females and >=1.5 mg/dL for males at Screening Visit
  • Subject has planned an elective surgical procedure in the coming 6 months
  • Subject has evidence of a secondary cause of primary immune thrombocytopenia purpura
  • Subject has a history of ongoing chronic infections
  • Subject has a family history of primary immunodeficiency
  • Subject has a clinically relevant active infection or has had a serious infection within 6 weeks prior to the first dose of IMP
  • Subject has a history of known inflammatory bowel disease, diverticular disease, and gastric or esophageal ulceration
  • Subject has experienced gastrointestinal bleed in the last 6 months prior to Screening Visit and/or has current gastritis or esophagitis
  • Subject has a medical history of thrombosis
  • Subject has a history of coagulopathy disorders other than ITP
  • Subject has received a within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP
  • Subject has had prior treatment with rituximab in the 6 months prior to the Baseline Visit
  • Subject has not completed the for the , biologics and other therapies
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    UCB7665 4 mg/kg

    Participants in this arm received 5 subcutaneous (sc) doses of UCB7665 (rozanolixizumab) 4 milligram per kilograms (mg/kg) at 1-week intervals.

    Drug: UCB7665

  • Experimental
    UCB7665 7 mg/kg

    Participants in this arm received 3 sc doses of UCB7665 (rozanolixizumab) 7 mg/kg at 1-week intervals.

    Drug: UCB7665

  • Experimental
    UCB7665 10 mg/kg

    Participants in this arm received 2 sc doses of UCB7665 (rozanolixizumab) 10 mg/kg at 1-week intervals.

    Drug: UCB7665

  • Experimental
    UCB7665 15 mg/kg

    Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 15 mg/kg.

    Drug: UCB7665

  • Experimental
    UCB7665 20 mg/kg

    Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 20 mg/kg.

    Drug: UCB7665

Interventions

  • * Intervention Type: Biological/Vaccine * Pharmaceutical Form: Powder for solution for infusion * Concentration: 100 mg/ml - Route of Administration: Subcutaneous infusion

    Also known as: rozanolixizumab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study

    TEAEs were defined as Adverse Events starting after the time of first Investigational Medicinal Product (IMP) administration up to and including 8 weeks after the final dose.

    Time frame: From Visit 2 (Week 1) until End of Study Visit or Early Termination (up to 12 weeks after the first investigational medicinal product (IMP) administration)

07

Results

Posted Jan 29, 2024

Participant flow

The study started to enroll patients in March 2016 and concluded in February 2019.

Participant flow — Overall Study
MilestoneUCB7665 4 mg/kgUCB7665 7 mg/kgUCB7665 10 mg/kgUCB7665 15 mg/kgUCB7665 20 mg/kg
Started1515121212
Completed1415121212
Not completed10000
Withdrew: Lack of efficacy10000

Outcome measures

PrimaryPercentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study

TEAEs were defined as Adverse Events starting after the time of first Investigational Medicinal Product (IMP) administration up to and including 8 weeks after the final dose.

Time frame:
From Visit 2 (Week 1) until End of Study Visit or Early Termination (up to 12 weeks after the first investigational medicinal product (IMP) administration)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study
percentage of participantsUCB7665 4 mg/kg (SS)UCB7665 7 mg/kg (SS)UCB7665 10 mg/kg (SS)UCB7665 15 mg/kg (SS)UCB7665 20 mg/kg (SS)
Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study80.060.058.391.7100

Adverse events

Collected over Adverse events were collected from Week 1 until the End-of-Study Visit (8 weeks following the final dose) (up to 12 weeks after the first dose of IMP). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UCB7665 4 mg/kg (SS)0/15 (0%)1/15 (6.7%)11/15 (73.3%)
UCB7665 7 mg/kg (SS)0/15 (0%)0/15 (0%)9/15 (60%)
UCB7665 10 mg/kg (SS)0/12 (0%)1/12 (8.3%)7/12 (58.3%)
UCB7665 15 mg/kg (SS)0/12 (0%)2/12 (16.7%)10/12 (83.3%)
UCB7665 20 mg/kg (SS)0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventUCB7665 4 mg/kg (SS)UCB7665 7 mg/kg (SS)UCB7665 10 mg/kg (SS)UCB7665 15 mg/kg (SS)UCB7665 20 mg/kg (SS)
ThrombocytopeniaBlood and lymphatic system disorders0/150/151/121/120/12
Platelet count decreasedInvestigations0/150/150/121/120/12
Genital haemorrhageReproductive system and breast disorders1/150/150/120/120/12
Most frequent other events
Showing 10 of 63
Most frequent other events
EventUCB7665 4 mg/kg (SS)UCB7665 7 mg/kg (SS)UCB7665 10 mg/kg (SS)UCB7665 15 mg/kg (SS)UCB7665 20 mg/kg (SS)
HeadacheNervous system disorders3/156/153/125/129/12
VomitingGastrointestinal disorders0/150/150/122/124/12
PyrexiaGeneral disorders0/150/151/121/123/12
DiarrhoeaGastrointestinal disorders1/152/151/122/122/12
ContusionInjury, poisoning and procedural complications0/150/150/121/122/12
Joint swellingMusculoskeletal and connective tissue disorders0/150/150/120/122/12
AnaemiaBlood and lymphatic system disorders1/151/150/121/120/12
Immune thrombocytopenic purpuraBlood and lymphatic system disorders0/150/150/120/121/12
Ear painEar and labyrinth disorders0/150/151/120/120/12
NauseaGastrointestinal disorders1/150/151/121/120/12

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all study participants who had received at least 1 infusion (full or partial infusion) of rozanolixizumab and was used for the analysis of safety data.

Age, Categorical
Age, Categorical(Participants)UCB7665 4 mg/kgUCB7665 7 mg/kgUCB7665 10 mg/kgUCB7665 15 mg/kgUCB7665 20 mg/kgTotal Title
<=18 years000000
Between 18 and 65 years7141011749
>=65 years8121517
Age, Continuous
Age, Continuous(years)UCB7665 4 mg/kgUCB7665 7 mg/kgUCB7665 10 mg/kgUCB7665 15 mg/kgUCB7665 20 mg/kgTotal Title
Mean59.1 ± 18.446.0 ± 15.946.3 ± 16.845.8 ± 14.656.1 ± 18.250.8 ± 17.4
Sex: Female, Male
Sex: Female, Male(Participants)UCB7665 4 mg/kgUCB7665 7 mg/kgUCB7665 10 mg/kgUCB7665 15 mg/kgUCB7665 20 mg/kgTotal Title
Female81177942
Male7455324
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UCB7665 4 mg/kgUCB7665 7 mg/kgUCB7665 10 mg/kgUCB7665 15 mg/kgUCB7665 20 mg/kgTotal Title
Asian200002
White131512121264
08

Study locations

29 sites
  • Tp0001 1101
    Adelaide, Australia
  • Tp0001 1302
    Pleven, Bulgaria
  • Tp0001 1301
    Sofia, Bulgaria
  • Tp0001 203
    Olomouc, Czechia
  • Tp0001 201
    Praha 10, Czechia
  • Tp0001 1201
    Tbilisi, Georgia
  • Tp0001 401
    Berlin, Germany
  • Tp0001 403
    Dusseldorf, Germany
  • Tp0001 404
    Muenchen, Germany
  • Tp0001 502
    Firenze, Italy
  • Tp0001 506
    Torino, Italy
  • Tp0001 503
    Udine, Italy
  • Tp0001 505
    Vicenza, Italy
  • Tp0001 601
    Chisinau, Moldova, Republic of
  • Tp0001 702
    Bialystok, Poland
  • Tp0001 703
    Gdańsk, Poland
  • Tp0001 701
    Lodz, Poland
  • Tp0001 704
    Poznan, Poland
  • Tp0001 705
    Warsaw, Poland
  • Tp0001 802
    Brasov, Romania
  • Tp0001 801
    Bucharest, Romania
  • Tp0001 803
    Craiova, Romania
  • Tp0001 902
    Madrid, Spain
  • Tp0001 903
    Madrid, Spain
  • Tp0001 901
    Valencia, Spain
  • Tp0001 1001
    London, United Kingdom
  • Tp0001 1002
    London, United Kingdom
  • Tp0001 1003
    London, United Kingdom
  • Tp0001 1004
    Truro, United Kingdom
09

References and documents

Publications

  • Robak T, Kazmierczak M, Jarque I, Musteata V, Trelinski J, Cooper N, Kiessling P, Massow U, Woltering F, Snipes R, Ke J, Langdon G, Bussel JB, Jolles S. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. Blood Adv. 2020 Sep 8;4(17):4136-4146. doi: 10.1182/bloodadvances.2020002003. PubMed 32886753 ↗
  • Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, Atherfold P, D'Hooghe LE, Finney H, Greenslade K, Hailu H, Kevorkian L, Lightwood D, Meier C, Munro R, Qureshi O, Sarkar K, Shaw SP, Tewari R, Turner A, Tyson K, West S, Shaw S, Brennan FR. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018 Oct;10(7):1111-1130. doi: 10.1080/19420862.2018.1505464. Epub 2018 Sep 12. PubMed 30130439 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Feb 2019, 35 months.

Results were first posted in Jan 2024, 4 years 11 months after primary completion.

Of 54 phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2016
First posted
Mar 24, 2016
StartActual
Mar 2, 2016
Primary completionActual
Feb 4, 2019
CompletionActual
Feb 4, 2019
Results first posted
Jan 29, 2024
Last update
Jan 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02718716
Lead sponsor
UCB Biopharma SRL
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Mar 2, 2016
Primary completion
Feb 4, 2019
Completion
Feb 4, 2019
Results posted
Jan 29, 2024
Last update
Jan 29, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion